Search results | heart

Reports

Congestive Heart Failure Partnering

Congestive Heart Failure Partnering provides understanding and access to the congestive heart failure partnering deals and agreements entered into by the worlds leading healthcare companies

Insights

Partnering with Takeda: Partnerships are at the heart of what they do

Takeda Pharmaceuticals is a top pharma company active in partnering, licensing and M&A in the pharmaceutical sector

Current Agreements Deal Analysis Update : October 2014

This month we provide you with an overview of deal analysis in the life science sectors, covering partnering, M&A and financing in September 2014.

Cardiovascular partnering – recent market research analysis 2009-2014

Recent market research analysis by Current Agreements shows that partnering in the last decade has seen an increase in cardiovascular deals with an increase in modern diagnostic technology development.

Current Agreements Deal Analysis Update : September 2014

This month we provide you with an overview of life science deal making activity, covering partnering, M&A and financing in August 2014.

Cubist Pharma, the next acquisition target for big pharmaceuticals

The timing may be right for a takeover of Cubist Pharmaceuticals.

SciClone Pharmaceuticals: Your marketing partner for China

Sciclone Pharmaceuticals is a specialty pharmaceutical company focused on developing and marketing products to treat oncology, infectious diseases and urology.

SciClone Pharmaceuticals: Big biotech partnering trends 2009-2014

SciClone Pharmaceuticals is a US based specialty company. The company focusses its efforts to widen its portfolio in China by in-licensing and acquiring rights to marketed products.

Medtronic in the talks to acquire Covidien

Medtronic Inc is in advanced talks to acquire rival Covidien Plc in a deal valued at $45 billion to $50 billion, people familiar with the matter said on Saturday.

Acorda Therapeutics: Maintaining an open patient dialogue to treat neurological diseases

Acorda Therapeutics is a commercial stage biopharmaceutical company identifying and developing treatments for neurological disorders including multiple sclerosis, spinal cord injury and disorders of the nervous system.

Takeda Pharmaceuticals

Takeda Pharmaceuticals is a top pharmaceutical company based in Osaka, Japan

Events

Sorry, your search returned no results.


Deals

Acquisition agreement for Boston Heart Diagnostics

Eurofins Scientific has signed a definitive agreement to acquire Boston Heart Diagnostics Corporation for an initial value of $140 million, subject to post-closing adjustments, plus an earn-out payment to the sellers that is expected to be in excess of $60 million upon achievement of certain milestones.

Latest M&A: HeartWare acquires CircuLite

Medical device marker, HeartWare International acquires CircuLite for $350 million.

$100 million financing for heart drug Vascepa acheived by Amarin

Amarin, a biopharmaceutical company,  was able to raise $100 million in non-equity financing that will help it form a sales force to launch its heart drug Vascepa.

Cleveland Heart in Private financing placement for $30 million

In a financing deal, Cleveland Heart has received a $30 million investment that will aid efforts to bring its version of the total artificial heart to market.

Private financing raises $26 million for SentreHeart

In a private financing venture, SentreHEART has raised $26 million, according to a regulatory filing with the U.S. Securities and Exchange Commission

Celladon completes $43 million financing to advance MYDICAR for the treatment of heart failure

Celladon Corporation, a biopharmaceutical company focused on the discovery and development of innovative treatments for cardiovascular diseases, announced today that it has completed a $43 million equity financing to advance its lead investigational product candidate MYDICAR for the treatment of heart failure.

Celera Corporation (CRA) Signs Agreement with Abbott Laboratories (ABT) for Distribution of CE-marked KIF6 Test to Identify Patients at Risk of Coronary Heart Disease

Exclusive distribution agreement to market Celera’s CE-marked KIF6 diagnostic test for use on Abbott’s CE-marked m2000™ instrument system.

Cardiome gets nod for marketing heart drug in EU; receives $30 million from Merck Sharp & Dohme

Cardiome Pharma Corp. has announced that it has earned a $30 million milestone payment from its collaboration with Merck (known as MSD outside the United States and Canada),

Novartis to pay Corthera up to $620M for heart drug rights

Novartis agreed to buy privately held U.S. group Cothera for $120 million, gaining rights to a heart failure drug.

Roche and SeqWright collaborate to elucidate the underlying genetic causes of heart disease

The research focuses on a major study to help identify possible genetic variants associated with dilated cardiomyopathy, a disease of heart muscle.